Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)
Status:
Active, not recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This is an open-label, non-controlled, non-randomized, phase I dose-finding, of Cabometyx +
Avelumab, to establish safety, feasibility, and the maximum tolerated dose (MTD) or
Recommended Phase 2 Dose (RP2D) of Cabometyx in combination with Avelumab, and to investigate
preliminary efficacy. The MTD or RP2D determined in this study will be used for a future
study to formally test efficacy. The MTD determined by dose escalation will be the
recommended Phase 2 dose.